Drug Profile
Research programme: haemolysin-induced pore blocker - Innovative Biologics
Alternative Names: IB201Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Innovative Biologics
- Class Cyclodextrins
- Mechanism of Action Cell membrane permeability inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pneumonia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pneumonia in USA (IV)